Effective delivery of large genes to the retina by dual AAV vectors
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Retinal gene therapy with adeno‐associated viral (AAV) vectors is safe and effective in humans. However, AAV's limited cargo capacity prevents its application to therapies of inherited retinal diseases due to mutations of genes over 5 kb, like Stargardt's disease (STGD) and Usher syndrome type IB (USH1B). Previous methods based on ‘forced’ packaging of large genes into AAV capsids may not be easily translated to the clinic due to the generation of genomes of heterogeneous size which raise safety concerns. Taking advantage of AAV's ability to concatemerize, we generated dual AAV vectors which reconstitute a large gene by either splicing (trans‐splicing), homologous recombination (overlapping), or a combination of the two (hybrid). We found that dual trans‐splicing and hybrid vectors transduce efficiently mouse and pig photoreceptors to levels that, albeit lower than those achieved with a single AAV, resulted in significant improvement of the retinal phenotype of mouse models of STGD and USH1B. Thus, dual AAV trans‐splicing or hybrid vectors are an attractive strategy for gene therapy of retinal diseases that require delivery of large genes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even though vector reconstitution in the retina has been detected for clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
From Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting (2017) · cites this paper as Trapani et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“it is worth remembering that the multiplicity of infection is about 10 4 - 10 5 vector particles at the level of the RPE, depending on the disease state at the time of treatment (Trapani et al., 2014; Ramachandran et al., 2017).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Trapani et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“advances in dual and triple AAV vectors with enhanced cargo capacity now allow for the delivery of larger genes [242], including anti-VEGF and complement regulatory molecules”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [242]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The hybrid dual AAV strategy was initially proposed by Gosh and colleagues in 2008 [54] and found to significantly improve transgene reassembly in a variety of studies thereafter [29,49].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In their study, Trapani et al. demonstrated that in vitro transduction with vectors with oversized genomes did not result in efficient transgene expression. 46”
From Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids (2016) · cites this paper as [46]
Experimental — accuracy not yet measured
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statistics and Computing · doi:10.1007/978-0-387-21706-2 · Cited by 24,305 · cited 1×
“…lipo-fuscin granules (Fig 5D) are expressed as discrete numbers, these were analyzed by deviance from a Negative Binomial generalized linear models (Venables & Ripley, 2002) WT versus Abca4 (cid:1) / (cid:1) neg P = 0.016; WT versus Abca4 (cid:1) / (cid:1) AK-ABCA4 P = 0.03; Abca4 (cid:1) /…”
InfluentialThe Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
A monomeric red fluorescent protein
Campbell, R. E., Tour, O., Palmer, A. E., Steinbach, P. A., Baird, G. S., Zacharias, D. A., & Tsien, R. Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082243699 · Cited by 2,365 · cited 1×
“The membrane was then analyzed by X-ray autoradiography using Amersham Hyperfilm TM MP (GE Healthcare Europe, GmbH).”
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“While AAV-mediated gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and…”
Allikmets, R., Singh, N., Sun, H., Shroyer, N. F., Hutchinson, A., Chidambaram, A., Gerrard, B., Baird, L., Stauffer, D., Peiffer, A., et al. (1997) · Nature Genetics · doi:10.1038/ng0397-236 · Cited by 1,435
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 4×
“Although the Abca4 (cid:1) / (cid:1) mouse model does not undergo severe PR degeneration (Wu et al , 2010a), the absence of the ABCA4-encoded all-trans retinal transporter in PR outer segments (Illing et al , 1997; Sun & Nathans, 1997) causes an accumulation of lipo-fuscin in PR as well as in RPE,…”
InfluentialWeng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 5×
“ABCA4 and MYO7A expression was normalized to Filamin A or Dysferlin for the in vitro and in vivo experiments, respectively.”
InfluentialMaguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865 · cited 2×
“…gene therapy is effective in animal models and in patients with inherited blinding conditions (Jacobson et al , 2006; Bainbridge et al , 2008; Maguire et al , 2008, 2009; Cideciyan et al , 2009; Simonelli et al , 2010), its application to diseases affecting the retina and requiring a…”
Self-citation
Cited by
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
“7 kb in size.(37,38,43) Promising results are being achieved also by applying this technology to some muscular diseases, and clinical development is currently being pursued for dysferlinopathy (ClinicalTrials.”
BackgroundSelf-citationEngineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Efforts are currently underway by multiple groups to develop dual AAV vector platforms that will promote delivery of large genes to PRs.108,109 Beyond monogenic disease, AAV is also being used to vectorize antivascular endothelial growth factor (VEGF) reagents to the retina via SRI to serve as a one-time treatment for…”
BackgroundAAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
“Potential solutions have been proposed to decrease vector immunogenicity,(152) and it is likely that more effective solutions than corticosteroid administration will be needed to tackle gene therapy strategies requiring high vector doses, such as those relying on dual AAV vectors.(153) Similar considerations are also…”
BackgroundAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities
Mathur, P., & Yang, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.020 · Cited by 330
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Al‐Moyed, H., Cepeda, A. P., Jung, S., Moser, T., Kügler, S., & Reisinger, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809396 · Cited by 230
Sensory Processing at Ribbon Synapses in the Retina and the Cochlea
Moser, T., Grabner, C. P., & Schmitz, F. (2020) · Physiological Reviews · doi:10.1152/physrev.00026.2018 · Cited by 209
Vector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
“Dual AAVmediated large gene delivery in mice (Dyka et al., 2014; Lopes et al., 2013; Reich et al., 2003a; Trapani et al., 2014) and in pigs (Colella et al., 2014) seems to overcome AAV's limited cargo capacity, extending its applicability to IR due to mutations in large genes.”
BackgroundMethodInfluentialSelf-citationTornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
“However, the efficiency of transgene expression achieved with either dual or triple AAV vectors in photoreceptors, which are the main therapeutic targets for most inherited retinal diseases, is lower than that achieved with single AAV vectors (4, 7, 8).”
BackgroundMethodInfluentialSelf-citationViral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
“Dual AAV vectors have shown therapeutic efficacy in mouse models of retinal disorders (Trapani et al., 2014).”
BackgroundGene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
“For use of AAV, there may be complementation mediated by the infected cell after coinfection with virus particles carrying different portions of the gene cassette (Colella et al. 2014; Puppo et al. 2014; Trapani et al. 2014).”
MethodExpressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids
Chamberlain, K., Riyad, J. M., & Weber, T. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.140 · Cited by 141
“But, interestingly, they also found that the vectors using the hybrid AP system expressed very poorly when compared with overlapping, trans-splicing, and hybrid-AK vectors.(46) Based on these results, the authors decided to use the trans-splicing and hybrid-AK vectors to transduce mouse photoreceptors and retinal pigm…”
BackgroundMethodResultInfluentialDyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128
“Previously, we and others have shown that fAAV-MYO7A is able to ameliorate the retinal phenotype of the shaker1 mouse (Colella et al., 2013; Lopes et al., 2013; Trapani et al., 2013).”
BackgroundTriple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
“demonstrated to be effective in the context of dual AAV vectors.(26) As a second recombinogenic region (at the 30 end of ED-AAV 2 and 50 end of ED-AAV 3), we used a 200-bp sequence (NM_000350.”
MethodResultSelf-citationGene therapy and genome surgery in the retina
DiCarlo, J. E., Mahajan, V. B., & Tsang, S. H. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120429 · Cited by 127
Omichi, R., Shibata, S. B., Morton, C. C., & Smith, R. J. H. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz129 · Cited by 130
“This limitation can be overcome by dual injection methods at the expense of transduction efficiency (116).”
BackgroundSeeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
“Indeed, a Phase I/II clinical trial testing the safety and efficacy of dual AAV in the retina of USHIB patients is being planned.iMore recently, AAV transfer capacity has been expanded up to 14 kb, albeit at the expense of efficiency, by adding a third vector to the dual system (triple AAV) [46].”
BackgroundSelf-citationEngineering Delivery Vehicles for Genome Editing
Nelson, C. E., & Gersbach, C. A. (2016) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-080615-034711 · Cited by 118
“For transgenes larger than the packaging capacity, dual AAV vector approaches have shown efficacy in vivo (127, 128), though some efficiency loss is expected with this method.”
BackgroundUsher syndrome: clinical features, molecular genetics and advancing therapeutics
Toms, M., Pagarkar, W., & Moosajee, M. (2020) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841420952194 · Cited by 133
Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
Bordet, T., & Behar-Cohen, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.038 · Cited by 120
Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease
Prado, D. A., Acosta-Acero, M., & Maldonado, R. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000660 · Cited by 114
“Dual-AAVs are another emerging alternative which can accommodate larger transgenes by splitting the full-length DNA into two components which later become reconstituted into the full gene once delivered to the target cells [8].”
BackgroundGene therapy for inherited retinal diseases: Progress and possibilities
Hu, M. L., Edwards, T. L., O’Hare, F., Hickey, D. G., Wang, J.-H., Liu, Z., & Ayton, L. N. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1880863 · Cited by 118
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
Adeno-associated Virus (AAV) Dual Vector Strategies for Gene Therapy Encoding Large Transgenes.
McClements, M. E., & MacLaren, R. E. (2017) · PubMed Central · Cited by 144
Retinoids and Retinal Diseases
Kiser, P. D., & Palczewski, K. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114407 · Cited by 108
“This limitation has been circumvented by using dual AAV vectors containing portions of the ABCA4 coding sequence that reconstitute the complete coding sequence in situ via concatemerization (Trapani et al. 2014).”
MethodNanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Emerging Gene Therapies for Genetic Hearing Loss
Ahmed, H., Shubina-Oleinik, O., & Holt, J. R. (2017) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-017-0634-8 · Cited by 110
“The trans-splicingmediated dual gene delivery approach was successfully implemented in several animal models (Cao et al. 2012; Trapani et al. 2013; Colella et al. 2014; Dyka et al. 2014; Tal-Goldberg et al. 2014; Wang et al. 2014; Fine et al. 2015).”
BackgroundMethodUSH2A-retinopathy: From genetics to therapeutics
Toualbi, L., Toms, M., & Moosajee, M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108330 · Cited by 116
Systemic delivery of adeno-associated viral vectors
Duan, D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.006 · Cited by 103
Zallocchi, M., Binley, K., Lad, Y., Ellis, S., Widdowson, P., Iqball, S., Scripps, V., Kelleher, M., Loader, J., Miskin, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094272 · Cited by 102
“Such studies may be possible using vectors that restrict MYO7A expression to either RPE or photoreceptor cells [30] and this would be useful for elucidating whether functional complementation via myosin VIIa expression directed specifically to either cell compartment is sufficient to rescue atransducin translocation t…”
BackgroundResultEfficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
Self-citationGene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G.-S. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 100
Guimaraes, T. A. C. D., Georgiou, M., Bainbridge, J. W. B., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316195 · Cited by 91
“36 Other AAV serotypes have also been identified, but the most extensively studied in ocular gene therapies are AAV2, AAV5 and AAV8.”
BackgroundTrapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94
“resulted in 50% ABCA4-expressing eyes (10).”
InfluentialSelf-citationmRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
Riedmayr, L. M., Hinrichsmeyer, K. S., Thalhammer, S. B., Mittas, D. M., Karguth, N., Otify, D. Y., Böhm, S., Weber, V. J., Bartoschek, M. D., Splith, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42386-0 · Cited by 103
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
“…clinically relevant large transgenes, such as ABCA4 or MYO7A, due to lack of proper controls (e.g., using oversized monocistronic vectors) and accurate protein quantification methods, determining parameters for clinical approaches has been lacking (Dyka et al., 2014; Trapani et al., 2014, 2015).”
BackgroundMethodDelivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors
Hirsch, M. L., Wolf, S. J., & Samulski, R. J. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_2 · Cited by 84
“Designs of trans-splicing constructs in the literature provide examples of the genetic arrangements and intronic sequences used previously [4, 6, 7, 12, 13, 24, 27].”
BackgroundInfluentialUnderstanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses
Bennett, A., Mietzsch, M., & Agbandje-McKenna, M. (2017) · Future Virology · doi:10.2217/fvl-2017-0011 · Cited by 82
Disease mechanisms and gene therapy for Usher syndrome
Géléoc, G. S. G., & El-Amraoui, A. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107932 · Cited by 84
Preclinical Efficacy And Safety Evaluation of AAV‐ OTOF in DFNB9 Mouse Model And Nonhuman Primate
Qi, J., Zhang, L., Tan, F., Zhang, Y., Zhou, Y., Zhang, Z., Wang, H., Yu, C., Jiang, L., Liu, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202306201 · Cited by 96
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
“With this, the capacity can be increased up to 9 kb [41,43,187].”
BackgroundBioengineering strategies for restoring vision
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00836-4 · Cited by 79
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
“…studies have shown the ability of hybrid vectors to reconstitute large transgenes, 52,72–74 at levels that were higher compared with the other dual AAV strategies side-by-side tested 52,72,73 and that resulted in improvement of the retinal phenotype of animal models of inherited retinal diseases.”
InfluentialSelf-citationAn Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story
Al‐Khuzaei, S., Broadgate, S., Foster, C. R., Shah, M., Yu, J., Downes, S. M., & Halford, S. (2021) · Genes · doi:10.3390/genes12081241 · Cited by 85
“However, this approach is limited by the dual vector being less able to transduce photoreceptors compared to single AAV vectors [178,179].”
BackgroundGene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Kumaran, N., Michaelides, M., Smith, A. J., Ali, R. R., & Bainbridge, J. W. B. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy005 · Cited by 68
Adeno-Associated Viral Vectors as a Tool for Large Gene Delivery to the Retina
Trapani, I. (2019) · Genes · doi:10.3390/genes10040287 · Cited by 73
Self-citationIn vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
“To transfer larger expression cassettes, dual vectors have been developed, which are based on the ability that AAVs can concatamerize by splicing, HDR, or a combination of both (Trapani et al., 2014a).”
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 65
“Recombination then occurs in co-infected cells, leading to functional expression of the therapeutic gene [Dyka et al., 2014; Trapani et al., 2014].”
BackgroundNovel therapeutics for Stargardt disease
Lu, L. J., Liu, J., & Adelman, R. A. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3619-8 · Cited by 72
Design of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 72
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
“CLUAP1 Clusterin associated protein 1 Photoreceptor ciliary transport ∼48 (14)”
BackgroundVectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
Usher Syndrome: Genetics and Molecular Links of Hearing Loss and Directions for Therapy
Whatley, M., Francis, A., Ng, Z. Y., Khoh, X. E., Atlas, M. D., Dilley, R. J., & Wong, E. Y. M. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.565216 · Cited by 68
Retinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56
Self-citationRamlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B., Steel, J. C., & Layton, C. J. (2019) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 57
“Their results showed that the overlapping AAV vectors produced a higher gene expression in cell culture when compared to fragmented or hybrid but this did not translate to in vivo experiments.(118) In contrast, Dyka et al showed that they were able to successfully achieve expression of MYO7A in both in vitro and in vi…”
ResultTowards the Clinical Application of Gene Therapy for Genetic Inner Ear Diseases
Lahlou, G., Calvet, C., Giorgi, M., Lecomte, M.-J., & Safieddine, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031046 · Cited by 57
Preclinical evaluation of the efficacy and safety of AAV1-hOTOF in mice and nonhuman primates
Zhang, L., Wang, H., Xun, M., Tang, H., Wang, J., Lv, J., Zhu, B., Chen, Y., Wang, D., Hu, S., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101154 · Cited by 57
“38,39 41 To increase recombinational ef fi ciency between the dual-AAVs, the AK/AP was placed downstream of the SD signal in the 5 0 half-vector and up-stream of the SA signal in the 3 0 half-vector (Figure S2A).”
BackgroundMethodNon-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles
Sun, D., Schur, R. M., Sears, A. E., Gao, S.-Q., Vaidya, A., Sun, W., Maeda, A., Kern, T., Palczewski, K., & Lu, Z.-R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.010 · Cited by 54
“Dual AAV strategies have been used to deliver two halves of theABCA4 gene to overcome the limited payload capacity of a single AAV.13,14 Although dual AAVs have been shown to mediate expression of the full-length ABCA4 protein in the photoreceptor outer segment of Abca4 / mice, they demonstrated low transduction effic…”
BackgroundInfluentialNew frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells
Daga, S., Donati, F., Capitani, K., Croci, S., Tita, R., Giliberti, A., Valentino, F., Benetti, E., Fallerini, C., Niccheri, F., et al. (2019) · European Journal of Human Genetics · doi:10.1038/s41431-019-0537-8 · Cited by 60
Stargardt disease and progress in therapeutic strategies
Huang, D., Jeffery, R. C. H., Aung-Htut, M. T., McLenachan, S., Fletcher, S., Wilton, S. D., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1966053 · Cited by 58
Marrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“splicing and hybrid vector strategies has shown efficient retinal pigment epithelium and photoreceptor transduction [29,30,101].”
BackgroundResultInfluentialDyka, F. M., Molday, L. L., Chiodo, V. A., Molday, R. S., & Hauswirth, W. W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.132 · Cited by 56
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy
Zhu, D., Schieferecke, A. J., Lopez, P. A., & Schaffer, D. V. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.03.010 · Cited by 56
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 50
“We and others have shown that the retina represents a favorable environment to develop dual AAV vector-based gene therapy approaches since co-transduction by multiple AAV vectors is quite efficient in the small subretinal space (63,67), especially of large animals (68).”
BackgroundSelf-citationThe Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 52
Self-citationKolesnik, V. V., Nurtdinov, R. F., Oloruntimehin, E. S., Karabelsky, A. V., & Malogolovkin, A. S. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1607 · Cited by 58
“106,116 In a follow-up study, the authors have reported the results of hybrid approach efficacy, pharmacokinetics and safety in mice and primates injected with AAV8.”
BackgroundPryadkina, M., Lostal, W., Bourg, N., Charton, K., Roudaut, C., Hirsch, M. L., & Richard, I. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.9 · Cited by 53
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 53
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Promising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2015) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 49
Targeting Splicing in the Treatment of Human Disease
Suñé-Pou, M., Prieto‐Sánchez, S., Boyero-Corral, S., Moreno‐Castro, C., Yousfi, Y. E., Suñé-Negre, J. M., Hernández-Munaín, C., & Suñé, C. (2017) · Genes · doi:10.3390/genes8030087 · Cited by 54
“Viral vectors have been used in certain cases of human diseases by changing the splicing pattern (even if the origin of the disease is not strictly related to the splicing process) such in SMA [81–83], DMD [84–88], cystic fibrosis [89,90], retinitis pigmentosa [91,92], aromatic L‐amino acid decarboxylase (AADC) defici…”
BackgroundDual and triple AAV delivery of large therapeutic gene sequences into the inner ear
Akil, O. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107912 · Cited by 52
Gene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 47
“However, until this is the case, subretinal delivery remains the most efficient administration route to target RPE and PR.”
BackgroundInfluentialSelf-citationTherapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
“Despite the original lack of success with overlapping ABCA4 dual vectors [67], it was considered that a viable strategy could still be obtained but that the success may lie in the region of homology between the two transgenes.”
BackgroundMethodInfluentialTherapeutic homology-independent targeted integration in retina and liver
Tornabene, P., Ferla, R., Llado-Santaeularia, M., Centrulo, M., Dell’Anno, M., Esposito, F., Marrocco, E., Pone, E., Minopoli, R., Iodice, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29550-8 · Cited by 44
Self-citationMolday, L. L., Wahl, D., Sarunic, M. V., & Molday, R. S. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddx400 · Cited by 48
AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model
Marino, M., Zhou, L., Rincón, M. Y., Callaerts-Végh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 36
Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
Barbon, E., Kawecki, C., Marmier, S., Sakkal, A., Collaud, F., Charles, S., Ronzitti, G., Casari, C., Christophe, O. D., Denis, C. V., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-00218-6 · Cited by 48
Ratican, S., Osborne, A., & Martin, K. R. G. (2018) · Neural Plasticity · doi:10.1155/2018/7108948 · Cited by 50
Hammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
“While AMD is a complex genetic disease, advances in dual and triple AAV vectors with enhanced cargo capacity now allow for the delivery of larger genes [242], including anti-VEGF and complement regulatory molecules, which could potentially be used in gene therapy for AMD.”
BackgroundHair Cell Transduction Efficiency of Single- and Dual-AAV Serotypes in Adult Murine Cochleae
Omichi, R., Yoshimura, H., Shibata, S. B., Vandenberghe, L. H., & Smith, R. J. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.007 · Cited by 46
“Viral titer, viral purifying and processing differences, and the presence of WPRE also can impact GFP expression.4,17 Interestingly, we found that AAV2 does not transduce vestibular hair cells despite robust transduction in cochlear hair cells, suggesting that AAV2 tropism is more specific than that of other AAVs.”
BackgroundResultInfluentialBankoti, K., Generotti, C. J., Hwa, T. P., Wang, L., O’Malley, B. W., & Li, D. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.005 · Cited by 47
“Overlapping dual AAV involves intentionally overlapping two specified sequences of demarcated fragments of the target transgene in two AAVs, and the joining of two transgenes to a single transgene occurs from a sequence of overlap.(44,45) Dual-overlapping AAV has a capacity of 8 8.”
BackgroundPrime Editing: An All-Rounder for Genome Editing
Lu, C., Kuang, J., Shao, T., Xie, S., Li, M., Zhu, L., & Zhu, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179862 · Cited by 48
“However, split-PE may have lower efficiency in vivo than intact PE because of imperfect construction of the spatial structure [48,49].”
BackgroundKurzawa‐Akanbi, M., Tzoumas, N., Corral-Serrano, J. C., Guarascio, R., STEEL, D. H., Cheetham, M. E., Armstrong, L., & Lako, M. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101248 · Cited by 44
Gene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
“The recombinogenic sequences used so far to induce the recombination between dual AAV hybrid vectors derive from regions of either the alkaline phosphatase gene (AP) (Ghosh et al. 2008, 2011) or the F1 phage genome (AK) (Trapani et al. 2014).”
BackgroundInfluentialSelf-citationRescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression
Vidal, P., Pagliarani, S., Colella, P., Verdera, H. C., Jauze, L., Gjorgjieva, M., Puzzo, F., Marmier, S., Collaud, F., Sola, M. S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.019 · Cited by 42
“These may include dual hybrid AAV carrying transgene-independent highly recombinogenic DNA sequences.(15,16) Additionally, small enhancer elements(42) and synthetic promoters(43) combined with AAV serotypes that efficiently target the muscle(44) could increase expression of the GDE transgene.”
BackgroundSelf-citationHolthaus, S.-M. K., Aristorena, M., Maswood, R. N., Semenyuk, O., Hoke, J., Hare, A., Smith, A. J., Mole, S., & Ali, R. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.038 · Cited by 42
“Intravitreal injections of 7m8 lead to the transduction of *25% of photoreceptors in mouse retinas.17 To exclude that transgene expression in photoreceptors contributed to the therapeutic effect, we also performed subretinal injections with AAV2/8, an AAV serotype commonly used to target photoreceptors and RPE.26 Cln3…”
MethodInfluentialAdeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
“Even if the reconstitution efficiency is low, phenotypic improvement in disease models have been reported in previous studies.(52,54,55) Furthermore, some genes involved in genetic disease are still larger than dual-AAVs capacity.”
ResultGene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration
Vagni, P., Perlini, L. E., Chenais, N. A. L., Marchetti, T., Parrini, M., Contestabile, A., Cancedda, L., & Ghezzi, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00945 · Cited by 45
Retinal gene therapy: an eye-opener of the 21st century
Askou, A. L., Jakobsen, T. S., & Corydon, T. J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0168-2 · Cited by 41
Pluripotent stem cell therapy for retinal diseases
Ahmed, I., Johnston, R. J., & Singh, M. S. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4747 · Cited by 41
“Dual AAV vectors have been studied as a way to produce large gene reconstitution by trans-splicing and/ or homologous recombination (19).”
Background
Metadata
- Authors
- Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., Farrar, G. J., Polishchuk, R., & Auricchio, A.
- Affiliations
- Telethon Institute Of Genetics And Medicine (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- University of Bologna (IT)
- Trinity College Dublin (IE)
- Federico II University Hospital (IT)
- Corresponding author
- Auricchio, Alberto
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2013-12-16
- Volume
- 6
- Issue
- 2
- Pages
- 194-211
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC3927955
- OpenAlex
- W2137826201
- Cited by
- 269
- References
- 82
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 17 · 2023: 24 · 2022: 18 · 2021: 24 · 2020: 31 · 2019: 22 · 2018: 22 · 2017: 23 · 2016: 9 · 2015: 17 · 2014: 13 · 2013: 1
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/3.0/ (tdm)
- creativecommons.org/licenses/by/3.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- European Research Council/ERC (282085)
- European Community's Seventh Framework Programme (242013)
- NIH (R24 RY019861‐01A)
- Italian Telethon Foundation (TGM11MT1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, trans-splicing, homologous recombination, hybrid vectors, Stargardt disease, photoreceptors, inherited retinal disease
- MeSH terms
- Stargardt Disease, Myosin VIIa, Dependovirus, Animals, Disease Models, Animal, Genetic Vectors, Humans, Injections, Lipofuscin, Macular Degeneration, Mice, Inbred C57BL, Myosins, Phenotype, Retina, Rhodopsin, Transduction, Genetic, Gene Transfer Techniques, ATP-Binding Cassette Transporters, Trans-Splicing, Photoreceptor Cells, Vertebrate, Melanosomes, Sus scrofa, Mice, Usher Syndromes, Retinal Pigment Epithelium, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.